Search results for:
Inflectra
inFLIXimab
- Restricted Miscellaneous Program Formulary
- Restricted Inflectra/Remicade/Renflexis/Avsola --> Restricted to Outpatient, rare situations where inFLIXimab would be given pre-surgery for cases of ulcerative colitis or Crohn's disease, for a long-term inpatient who has not responded to other options,
- Restricted Inflectra/Remicade/Renflexis/Avsola --> Kawasaki Disease, or immunotherapy induced severe colitis unresponsive to high dose steroids.
- Restricted
Drug Name |
Form |
Strength |
Formulary Unrestricted |
Formulary Restricted |
Non-Formulary |
Interchange |
Inflectra |
POWDER FOR INJECTION, INTRAVENOUS |
100 mg |
|
|
|
|
Infliximab-axxq (Avsola) |
POWDER FOR INJECTION, INTRAVENOUS |
100 mg |
|
|
|
|
Remicade |
POWDER FOR INJECTION, INTRAVENOUS |
100 mg |
|
|
|
|
Renflexis |
POWDER FOR INJECTION, INTRAVENOUS |
100 mg |
|
|
|
|
Last updated: Mar. 19, 2024
All infliximab biosimilars are classified as therapeutically equivalent and interchangeable for the FDA-approved indications. The most economical biosimilar product will be utilized based on cost and reimbursements at the time.
For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents
Drug reviewed for Outpatient Infusion (updated May 7, 2021)
Drug Alert: Inflectra Medication Guide
Drug Alert: Remicade Medication Guide
Drug Alert: Renflexis Medication Guide
Formulary, Restricted:
Dose Rounding: For inFLIXimab product, round dose nearest 50 mg for patients 18 years and over.
Reviewed: March 28, 2006 and Febuary 26, 2013 (Dose Rounding) and 28 March 2017 (Inflectra), and 27 Feb 2018 (Kawasaki Disease), and 26 June 2018 (steroid refractory immunotherapy-induced colitis), and 24 July 2018 (Renflexis).